Clinical Impact of Residual C-Peptide Secretion in Type 1 Diabetes on Glycemia and Microvascular Complications.
Anita JeyamHelen Martina ColhounStuart McGurnaghanLuke BlackbournTimothy J McDonaldTimothy James McDonaldJohn A McKnightMark W J StrachanAlan W PatrickJohn ChalmersRobert S LindsayJohn R PetrieRobert S LindsayAndrew CollierSandra MacRuryPaul M McKeiguenull nullPublished in: Diabetes care (2020)
These results in a large representative cohort suggest that even minimal residual C-peptide secretion could have clinical benefit in type 1 diabetes, in contrast to a follow-up study of the Diabetes Control and Complications Trial (DCCT) intensively treated cohort where an effect on hypoglycemia was seen only at C-peptide levels ≥130 pmol/L. This has obvious implications for the design and evaluation of trials of interventions to preserve or restore pancreatic islet function in type 1 diabetes.